Titel

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)

Kurzzusammenfassung

Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.

Zentren/Kontakt:

Universitätsklinikum Hamburg-Eppendorf (UKE), Dr. Stefan Schmiedel

Klinikum rechts der Isar, Technische Universität München, PD Dr. Christoph D. Spinner

Details

 

Stand: 20.05.2020, Quelle: www.clinicaltrials.gov

Menü